Navigation Links
Beaumont Hospital, Royal Oak Treats Its First Patients With Elekta Axesse
Date:10/30/2007

combination of accuracy, flexibility and dose control. Dr. Frank Vicini, M.D., chief of Oncology, Beaumont Cancer Institute, Beaumont Hospitals, says the three-dimensional kV volumetric imaging greatly improves the accuracy of tumor targeting. "Elekta Axesse is highly accurate because the real-time imager enables us to adjust, at the time of treatment, the shape and intensity of the radiation delivered."

Flexibility is vital to any successful radiation treatment, says Dr. Vicini. Elekta Axesse allows for multiple energy options and beam shaping options for efficient dose delivery and optimal target conformality, so healthy tissue is spared. "Quite simply, Elekta Axesse offers better cancer control and fewer side effects," Dr. Vicini says.

A history of technological collaboration

Beaumont Hospital, Royal Oak physicians have a nearly 20-year history of partnering with the Elekta R&D team. The hospital has made vital contributions to the development of pioneering 3D imaging and treatment technology. "We have done research together that has contributed to the development of Elekta Synergy(R) and Elekta Axesse, and we continue to be strong partners in advancing treatment for patients," Dr. Martinez says.

About Elekta

Elekta is an international medical-technology group, providing advanced clinical solutions, comprehensive patient information management systems and services for improved cancer care and management of brain disorders. All of Elekta's solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective.

Clinical, treatment, and information system solutions include, among others, Leksell Gamma Knife(R) for non-invasive treatment of brain disorders, Elekta Axesse(TM) for stereotactic radiation therapy and radiosurgery and Elekta Synergy(R) for intensity modulated and image guided radiation therapy (IMRT and IGRT). Together with IMPAC Medical Systems,
'/>"/>

SOURCE Elekta, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. The Genesis of Gendicine: The Story Behind the First Gene Therapy
2. Midwest life science stocks sizzle in a tepid first quarter
3. Morgridge Institute for Research seeks first CEO
4. Sonic Foundry reports first cash-positive quarter
5. Angel investors commit $12.7B in first half of `06
6. Aurora team implants Wisconsins first total artificial heart
7. First half of 2006 roundup: Big Pharma trumps biotech
8. GE announces first installation of Discovery VCT
9. GE Healthcare enjoys robust growth in first quarter
10. Madison asks for wireless bids; airport, downtown would be first
11. Tech Digest: Inacom, PKWare at Infosecurity, Firstlogic, Teklynx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/18/2010)... March 18 /PRNewswire/ - Norgen Biotek Corp., ... on advancing powerful tools for nucleic acids (NA) and ... new kits for nucleic-acid based diagnostics. Norgen makes best-in-class ... has recognized that high quality sample preparation is the ...
(Date:3/18/2010)... ... resource , ... -- The Structural Genomics Knowledgebase (SGKB), a one-stop shop for information ... provide free comprehensive training and outreach programs for its online protein “portal” located at ...
(Date:3/17/2010)... Research , an English-language journal jointly published by Springer and ... Index-Expanded (SCI-E). The academic journal, founded in July 2008, ... 1. Nano Research is part of Springer,s Chinese ... , Nano Research is an international, interdisciplinary journal ...
(Date:3/17/2010)... March 17  OriGene Technologies, Inc., a ... a $16 million Series B financing led ... Zero2IPO. OriGene,s previous investors Morningside Venture Investments ... this round.  The proceeds from the funding will be ...
Breaking Biology Technology:Norgen Biotek Transitions into Diagnostics with the Launch of over 30 New Kits for Nucleic Acid-Based Diagnostics 2Norgen Biotek Transitions into Diagnostics with the Launch of over 30 New Kits for Nucleic Acid-Based Diagnostics 3The Protein Structure Initiative announces free OpenHelix tutorial and training materials for the Structural Genomics Knowledgebase (SGKB) 2The Protein Structure Initiative announces free OpenHelix tutorial and training materials for the Structural Genomics Knowledgebase (SGKB) 3The Protein Structure Initiative announces free OpenHelix tutorial and training materials for the Structural Genomics Knowledgebase (SGKB) 4China's first open-access journal Nano Research listed in Science Citation Index 2OriGene Technologies Raises $16 Million to Build the Largest Collection of Next Generation Monoclonal Antibodies (TrueMAB(TM)) to Cover the Majority of Human Proteome 2OriGene Technologies Raises $16 Million to Build the Largest Collection of Next Generation Monoclonal Antibodies (TrueMAB(TM)) to Cover the Majority of Human Proteome 3
... The 2009 Frost & Sullivan European Drug Discovery ... in recognition of its active role in the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )These test kits, used ... improve the effectiveness of drug discovery and development ...
... in cell phones, digital cameras and other consumer ... green technology in performance (converting light into electricity), ... to be improved before they can qualify for ... if photoconducting materials are to be widely used ...
... (OTC Bulletin Board: TBIO) today announced financial results for the ... financial results are presented in the tables that follow. Fourth ... of $219,000 or $0.00 per share for the fourth quarter ... or $0.00 per share for the fourth quarter of 2007.Net ...
Other Biology Technology:Frost & Sullivan European Drug Discovery Product Innovation Award Bestowed on Xenometrix AG 2Frost & Sullivan European Drug Discovery Product Innovation Award Bestowed on Xenometrix AG 3Zinc oxide gives green shine to new photoconductors 2Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 2Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 3Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 4Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 5Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 6Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 7Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 8
(Date:3/21/2010)... A potential new energy source so controversial that people ... to acceptance by the mainstream scientific community. That,s the ... scientific sessions on the topic "cold fusion" ... the Moscone Center during the 239th National Meeting of ... scientists were afraid to speak about ,cold fusion, to ...
(Date:3/18/2010)... that commonly develop in early infancy are generally ... or destruction and sometimes obstruction of vision or breathing. ... corticosteroids such as dexamethasone or prednisone. But steroids have ... of action in hemangioma has remained a mystery. Researchers ...
(Date:3/18/2010)... The Center for Wireless Information Network Studies (CWINS) at ... million award from the National Institute of Standards and ... propagation of radio waves around and through the human ... computer engineering and director of CWINS, the research will ...
Breaking Biology News(10 mins):'Cold fusion' moves closer to mainstream acceptance 2'Cold fusion' moves closer to mainstream acceptance 3'Cold fusion' moves closer to mainstream acceptance 4Stem cells used to model infant birth defect 2Stem cells used to model infant birth defect 3WPI receives $1.2 million NIST award for pioneering study of wireless body area networks 2WPI receives $1.2 million NIST award for pioneering study of wireless body area networks 3Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial 50396 1Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial 50396 2Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial 50396 3Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial 50396 4Canadian Bio Med Attacks Worlds Leading Cause of Blindness 50393 1Canadian Bio Med Attacks Worlds Leading Cause of Blindness 50393 2Al Copeland Day Lives on Through Efforts To Cure Merkel Cell Carcinoma 50390 1Al Copeland Day Lives on Through Efforts To Cure Merkel Cell Carcinoma 50390 2Al Copeland Day Lives on Through Efforts To Cure Merkel Cell Carcinoma 50390 3
... genetic factors and certain adverse events related to smallpox ... issue of The Journal of Infectious Diseases, now available ... other live vaccines. , Immunization against infectious agents has ... and the eradication of smallpox from the world is ...
... among many college students involves "pulling all-nighters", or a ... with lower grade-point averages compared to those who make ... will be presented Wednesday at SLEEP 2007, the 21st ... , "Sleep in college students is generally inadequate, irregular ...
... of papers that promise to reshape our understanding of ... traditional view of our genetic blueprint as a tidy ... network in which genes, along with regulatory elements and ... for proteins, interact in overlapping ways not yet fully ...
Other Biology News:Genetic factors are linked to fever following smallpox vaccination 2New findings challenge established views on human genome 2New findings challenge established views on human genome 3New findings challenge established views on human genome 4
Xanthine Oxidase (Bovine Buttermilk). Monospecific by IEP. Some cross reactivity with Xanthine Oxidase of other species and tissues may occur....
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Low melting point. Ideally suited for in gel enzymatic reactions. Gelling temp. 24-28C Melting temp. 65C. EEO 0.12 Resolution 0.5-20 kb; Rnase/Dnase: none detected....
...
Biology Products: